Document is current
Any future updates will be listed below
-
Authors
Vavoulis, Dimitrios V. https://orcid.org/0000-0002-3984-1507
Cutts, Anthony
Thota, Nishita
Brown, Jordan https://orcid.org/0009-0007-3119-9701
Sugar, Robert
Rueda, Antonio
Ardalan, Arman
Howard, Kieran https://orcid.org/0000-0003-3335-4940
Matos Santo, Flavia https://orcid.org/0009-0000-4961-5450
Sannasiddappa, Thippesh
Miller, Bronwen
Ash, Stephen
Liu, Yibin https://orcid.org/0000-0003-3451-0212
Song, Chun-Xiao https://orcid.org/0000-0002-7781-6521
Nicholson, Brian D. https://orcid.org/0000-0003-0661-7362
Dreau, Helene
Tregidgo, Carolyn
Schuh, Anna https://orcid.org/0000-0002-3938-8490
- License Information
-
More Information
Article History
Received: 4 January 2024
Accepted: 5 December 2024
First Online: 8 January 2025
Competing interests
: A.S. is on the advisory board for Janssen and BeiGene and is the Founder of SERENOx. She also receives research funding from AstraZeneca and Janssen and in-kind contributions from Illumina and Oxford Nanopore Technologies. BDN has received research funding from GRAIL and is an unpaid member of the GRAIL Clinical Advisory Group. D.V.V., A.C. and H.D. own shares in SerenOx. N.T., J.B., R.S., A.R., T.S., B.M., Y.B.L. and C.T. were employees at Exact Sciences Innovation LTD for the duration of the study. The remaining authors declare no competing interests.
